
Group 1 - The core viewpoint of the article highlights that the recent policy optimizations are likely to drive a recovery in the pharmaceutical industry, particularly benefiting innovative drugs and medical devices [1] - The China National Healthcare Security Administration has indicated that the upcoming batch of centralized procurement will optimize rules, moving away from solely considering the lowest bid, which supports the development of innovative drugs and medical devices [1] - The medical device sector is expected to benefit from these policy changes, with a notable performance increase of 4.4% in the medical device sub-sector of the A-share pharmaceutical sector during the fourth week of July 2025 [1] Group 2 - The Guotai ETF (159377) tracking the innovative pharmaceutical index (399275) has seen a daily increase of over 2.1%, reflecting the positive sentiment in the market [1] - This index selects listed companies in the pharmaceutical, medical device, and medical service sectors from the ChiNext market, focusing on innovation and growth to represent the overall performance and development trends of China's pharmaceutical and biotechnology industry [1]